NCT05036421 is a Phase 3 clinical trial of Empagliflozin 10 milligram in Pharmacogenomic, sponsored by Ain Shams University.

Who is sponsoring NCT05036421?

NCT05036421 is sponsored by Ain Shams University.

What drugs are being tested in NCT05036421?

Interventions in NCT05036421: Empagliflozin 10 milligram.

What condition does NCT05036421 study?

NCT05036421 studies Pharmacogenomic, Pharmacokinetics.

Is NCT05036421 still recruiting?

NCT05036421 is currently completed. Last updated 14 February 2023.

Last reviewed 2023-02-14 · How we verify

NCT05036421

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Completed Phase 3 Last updated 14 February 2023

What this trial tests

Phase 3 trial testing Empagliflozin 10 milligram in Pharmacogenomic in 18 participants. Completed in 20 May 2022.

Timeline

15 February 2022

Primary endpoint
20 May 2022

20 May 2022

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	18
Start date	15 February 2022
Primary completion	20 May 2022
Estimated completion	20 May 2022
Sites	1 location across Egypt

Drugs / interventions tested

Empagliflozin 10 milligram — full drug profile →

Conditions studied

Pharmacogenomic — all drugs for Pharmacogenomic →
Pharmacokinetics — all drugs for Pharmacokinetics →

Sponsor

Ain Shams University

Who can join

Adults 18 to 45, male only, with Pharmacogenomic or Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this works is to investigate the effect of genetic polymorphism of snps on human response to treatment with empagliflozin and its correlation with with pharmacokinetic parameters in Egyptian subjects

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05036421 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 14 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05036421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing